Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV-1 resistance mutation.
Stirrup OT., Asboe D., Pozniak A., Sabin CA., Gilson R., Mackie NE., Tostevin A., Hill T., Dunn DT., UK HIV Drug Resistance Database and the UK Collaborative HIV Cohort None.
OBJECTIVES: The aim of the study was to investigate whether lamivudine (3TC) or emtricitabine (FTC) use following detection of M184V/I is associated with better virological outcomes. METHODS: We identified people with viruses harbouring the M184V/I mutation in UK multicentre data sets who had treatment change/initiation within 1 year. We analysed outcomes of viral suppression (